诊断学理论与实践››2017,Vol. 16››Issue (04): 437-441.doi:10.16150/j.1671-2870.2017.04.020
黄新韵, 胡佳佳, 李彪
收稿日期:2017-03-17出版日期:2017-08-25发布日期:2017-08-25通讯作者:李彪 E-mail: lb10363@rjh.com.cn基金资助:
Received:2017-03-17Online:2017-08-25Published:2017-08-25中图分类号:
黄新韵, 胡佳佳, 李彪.18F-FDG PET/CT显像在淋巴瘤疗效评估中的应用进展[J]. 诊断学理论与实践, 2017, 16(04): 437-441.
| [1] Chen W, Zheng R, Zeng H, et al.The incidence and mortality of major cancers in China, 2012[J]. Chin J Cancer,2016,35(1):73. [2] Weiler-Sagie M, Bushelev O, Epelbaum R, et al.(18)F-FDG avidity in lymphoma readdressed: a study of 766 patients[J]. J Nucl Med,2010,51(1):25-30. [3] Eichenauer DA, Engert A, André M, et al. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2014,25(Suppl 3):iii70-iii75. [4] Tilly H, Gomes da Silva M, Vitolo U, et al. Diffuse large B-cell lymphoma(DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2015,26( Suppl 5):v116-v125. [5] Dreyling M, Ghielmini M, Rule S, et al.Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol,2016,27(suppl 5):v83-v90. [6] Cheson BD, Horning SJ, Coiffier B, et al.Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group[J]. J Clin Oncol,1999,17(4):1244. [7] Cheson BD, Pfistner B, Juweid ME, et al.Revised response criteria for malignant lymphoma[J]. J Clin Oncol,2007,25(5):579-586. [8] Meignan M, Gallamini A, Meignan M, et al.Report on the First International Workshop on Interim-PET-Scan in Lymphoma[J]. Leuk Lymphoma,2009,50(8):1257-1260. [9] Fallanca F, Alongi P, Incerti E, et al.Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC)[J]. Eur J Nucl Med Mol Imaging,2016,43(10):1837-1848. [10] Cheson BD, Fisher RI, Barrington SF, et al.Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification[J]. J Clin Oncol,2014,32(27):3059-3068. [11] Biggi A, Gallamini A, Chauvie S, et al.International va-lidation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers[J]. J Nucl Med,2013,54(5):683-690. [12] Barrington SF, Mikhaeel NG, Kostakoglu L, et al.Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group[J]. J Clin Oncol,2014,32(27):3048-3058. [13] Pregno P, Chiappella A, Bellò M, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with ritu-ximab-CHOP[J]. Blood,2012 Mar 1,119(9):2066-73. [14] Dupuis J, Berriolo-Riedinger A, Julian A, et al.Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS[J]. J Clin Oncol,2012,30(35):4317-4322. [15] Juweid ME, Stroobants S, Hoekstra OS, et al.Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma[J]. J Clin Oncol,2007,25(5):571-578. [16] Boellaard R, Delgado-Bolton R, Oyen WJ, et al.FDG PET/CT: EANM procedure guidelines for tumour ima-ging: version 2.0[J]. J Clin Oncol,2007,25(5):571-578. [17] Itti E, Lin C, Dupuis J, et al.Prognostic value of interim18F-FDG PET in patients with diffuse large B-Cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy[J]. J Nucl Med,2009,50(4):527-533. [18] Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma[J]. Blood,2011 Jul 7,118(1):37-43. [19] Safar V, Dupuis J, Itti E, et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab[J]. J Clin Oncol, 2012 Jan 10,30(2):184-90. [20] Nols N, Mounier N, Bouazza S, et al.Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma[J]. Leuk Lymphoma,2014,55(4):773-780. [21] Agostinelli C, Gallamini A, Stracqualursi L, et al.The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study[J]. Lancet Haematol,2016,3(10):e467-e479. [22] Adams HJ, Nievelstein RA, Kwee TC.Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis[J]. Br J Haematol,2015,170(3):356-366. [23] Micallef IN, Maurer MJ, Wiseman GA, et al.Epratuzu-mab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma[J]. Blood,2011,118(15):4053-4061. [24] Adams HJ, Kwee TC.Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis[J]. Crit Rev Oncol Hematol,2016,106:55-63. [25] Dührsen U, Hüttmann A, Jöckel KH, et al.Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial[J]. Leuk Lymphoma,2009,50(11):1757-1760. [26] Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, et al.18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review[J]. Haematologica,2006,91(4):522-529. [27] Cerci JJ, Trindade E, Pracchia LF, et al.Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy[J]. J Clin Oncol,2010,28(8):1415-1421. [28] Barnes JA, LaCasce AS, Zukotynski K, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma[J]. Ann Oncol,2011,22(4):910-915. [29] Trotman J, Fournier M, Lamy T, et al.Positron emission tomography-computed tomography(PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants[J]. J Clin Oncol,2011,29(23):3194-3200. [30] Adams HJ, Nievelstein RA, Kwee TC.Outcome of Hodgkin Lymphoma Patients With a Posttreatment18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET)-negative residual mass: systematic review and meta-analysis[J]. Pediatr Hematol Oncol,2015,32(8):515-524. [31] Dabaja BS, Phan J, Mawlawi O, et al. Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma[J]. Leuk Lymphoma,2013 Dec,54(12):2631-2638. [32] Liedtke M, Hamlin PA, Moskowitz CH, et al.Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient population[J]. Ann Oncol,2006,17(6):909-913. [33] Lamonica D, Graf DA, Munteanu MC, et al.18F-FDG PET for measurement of response and prediction of outcome to relapsed or refractory mantle cell lymphoma therapy with bendamustine-rituximab[J]. J Nucl Med,2017,58(1):62-68. [34] Chang Y, Fu X, Sun Z, et al.Utility of baseline, interim and end-of-treatment18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase[J]. Sci Rep,2017,7:41057. [35] Ham JS, Kim SJ, Choi JY, et al.The prognostic value of interim and end-of-treatment PET/CT in patients with newly diagnosed peripheral T-cell lymphoma[J]. Blood Cancer J,2016,6:e395. [36] van Waarde A, Cobben DC, Suurmeijer AJ, et al. Selectivity of18F-FLT and18F-FDG for differentiating tumor from inflammation in a rodent model[J]. J Nucl Med,2004,45(4):695-700. [37] Minamimoto R, Fayad L, Advani R, et al.Diffuse Large B-Cell lymphoma: prospective multicenter comparison of early interim FLT PET/CT [38] Jauw YW, Zijlstra JM, de Jong D, et al. Performance of 89Zr-Labeled-Rituximab-PET as an imaging biomarker to assess CD20 targeting: A pilot study in patients with relapsed/refractory diffuse large B cell lymphoma[J]. PLoS One,2017,12(1):e0169828. |
| [1] | 屈骞, 海汪溪, 胡生焰, 张敏, 陈肖玥, 周熠磊, 王瑾, 胡晓平, 李彪, 胡佳佳.多巴胺转运蛋白显像探针18F-FP-CIT的AllinOne模块自动化制备及大鼠基底节Micro PET/CT显像[J]. 诊断学理论与实践, 2022, 21(04): 482-489. |
| [2] | 冯国伟, 张晓娟, 郭睿, 关哲, 王越.治疗前18F-FDG PET/CT显像对结外NK/T细胞淋巴瘤的预后判断价值[J]. 诊断学理论与实践, 2021, 20(06): 533-539. |
| [3] | 岳婧婧, 宋琦, 江旭峰, 王黎, 赵维莅, 严福华.磁共振全身扩散加权成像结合T2WI抑脂序列与FDG-PET/CT在初发淋巴瘤分期及病灶检出的对比研究[J]. 诊断学理论与实践, 2021, 20(06): 540-546. |
| [4] | 范春丽, 吴涛, 薛锋, 胡文雪, 王存邦, 白海.MUM1/IRF4阳性弥漫大B细胞淋巴瘤一例治疗报告并文献复习[J]. 诊断学理论与实践, 2021, 20(04): 399-400. |
| [5] | 赵茜, 赵肖庆, 刁立诚, 孙菲, 郑捷, 朱雪梅, 曹华.伴皮肤紫癜的原发性干燥综合征患者的临床特征分析[J]. 诊断学理论与实践, 2021, 20(02): 155-160. |
| [6] | 沈小雁, 郑捷.2005年至2018年皮肤淋巴瘤WHO-EORTC分类标准的发展与比较[J]. 诊断学理论与实践, 2021, 20(01): 15-20. |
| [7] | 李芹芹, 金晓龙, 袁菲.儿童系统性EB病毒阳性T细胞淋巴瘤临床病理分析一例及文献复习[J]. 诊断学理论与实践, 2020, 19(1): 63-68. |
| [8] | 孟磊俊, 张晶, 王雪莉, 李治, 张泓, 曾乃燕.儿童伯基特淋巴瘤中差异表达基因的鉴定及临床应用[J]. 诊断学理论与实践, 2020, 19(03): 248-257. |
| [9] | 丁燕飞, 陈平, 罗方秀, 吴云林.以反复上消化道出血为首发表现的套细胞淋巴瘤一例[J]. 诊断学理论与实践, 2020, 19(02): 191-194. |
| [10] | 杨巧, 王佩, 王璐.甲状腺细针穿刺细胞学诊断霍奇金淋巴瘤1例[J]. 诊断学理论与实践, 2019, 18(2): 215-217. |
| [11] | 房莹, 吴东, 常春康.癌基因与抑癌基因在伯基特淋巴瘤发生发展中的研究进展[J]. 诊断学理论与实践, 2019, 18(06): 630-633. |
| [12] | 王燕, 宋琦.磁共振全身弥散加权成像在淋巴瘤临床诊疗方面的应用价值及研究进展[J]. 诊断学理论与实践, 2019, 18(06): 692-697. |
| [13] | 杨志芳, 方国平, 詹维伟, 吉日.去分化实体型甲状腺乳头状癌伴黏膜相关淋巴组织结外边缘区淋巴瘤1例病理特征并文献分析[J]. 诊断学理论与实践, 2019, 18(05): 548-554. |
| [14] | 沈文斌, 郭睿, 李彪.18F-FDG PET/CT代谢参数在NK/T细胞淋巴瘤预后价值的评估[J]. 诊断学理论与实践, 2019, 18(03): 349-352. |
| [15] | 马媛媛, 王燕, 宋琦, 陈克敏, 赵夏, 王黎, 江旭峰, 赵维莅, 严福华.肺原发性淋巴瘤的CT影像学特点及文献复习[J]. 诊断学理论与实践, 2018, 17(05): 533-537. |
| 阅读次数 | ||||||
| 全文 |
|
|||||
| 摘要 |
|
|||||
